Zidovudine-phosphate-didanosine dimer

Drug Profile

Zidovudine-phosphate-didanosine dimer

Alternative Names: AZT-P-ddI; IVX-E-59; Scriptene

Latest Information Update: 12 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Corporation
  • Developer SSP Co
  • Class Antiretrovirals; Azides; Nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Sep 2003 No development reported - Phase-II for HIV infections treatment in USA (unspecified route)
  • 28 Jun 2002 Discontinued - Preclinical for HIV infections treatment in Japan (unspecified route)
  • 02 Dec 1999 SS Pharmaceuticals is now called SSP Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top